L
0.959
-0.01 (-0.95%)
| Previous Close | 0.968 |
| Open | 0.968 |
| Volume | 1,338,400 |
| Avg. Volume (3M) | 1,421,840 |
| Market Cap | 182,988,064 |
| Price / Sales | 22.42 |
| Price / Book | 2.16 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2026 |
| Operating Margin (TTM) | -1,508.09% |
| Diluted EPS (TTM) | -1.17 |
| Quarterly Revenue Growth (YOY) | -17.30% |
| Total Debt/Equity (MRQ) | 206.15% |
| Current Ratio (MRQ) | 0.750 |
| Operating Cash Flow (TTM) | -43.99 M |
| Levered Free Cash Flow (TTM) | -28.50 M |
| Return on Assets (TTM) | -92.04% |
| Return on Equity (TTM) | -1,897.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Lucid Diagnostics Inc. | Mixed | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.50 |
|
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 34.54% |
| % Held by Institutions | 10.13% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |